CJM-112
CJM-112 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A) . CJM-112 is promising for research of inflammatory diseases, such as hidradenitis suppurativa associated with abnormal IL-17A-related pathways[1].
Product Specifications
UNSPSC
12352203
Target
Interleukin Related
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
[CJM-112]
References & Citations
[1]Maarouf M, et al. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatolog Treat. 2018 Aug;29 (5) :441-449.|[2]Maarouf M, et al. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatolog Treat. 2018 Aug;29 (5) :441-449.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Isoform
IL-17
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6475992-01 0.2 mL
FKBP1B, NT (E6) (h-FKBP-12, Immunophilin FKBP12.6, 12.6kD FK506-binding Protein, 12.6kD FKBP, FKBP-12.6, Rotamase, FK506-binding Protein 1B, FKBP-1B, Peptidyl-prolyl cis-trans Isomerase FKBP1B, PPIase FKBP1B, FKBP12.6, FKBP1L, FKBP9, OTK4) (FITC)
Sign In for Pricing
View Details MBS6475992-02 5x 0.2 mL
FKBP1B, NT (E6) (h-FKBP-12, Immunophilin FKBP12.6, 12.6kD FK506-binding Protein, 12.6kD FKBP, FKBP-12.6, Rotamase, FK506-binding Protein 1B, FKBP-1B, Peptidyl-prolyl cis-trans Isomerase FKBP1B, PPIase FKBP1B, FKBP12.6, FKBP1L, FKBP9, OTK4) (FITC)
Sign In for Pricing
View Details 
MBS6472304-01 0.1 mL
DCD, CT (Dermcidin, Preproteolysin, Survival-promoting Peptide, DCD-1, DSEP, AIDD) (MaxLight 750)
Sign In for Pricing
View Details MBS6472304-02 5x 0.1 mL
DCD, CT (Dermcidin, Preproteolysin, Survival-promoting Peptide, DCD-1, DSEP, AIDD) (MaxLight 750)
Sign In for Pricing
View Details